Here are the 10-Q quarterly reports from Standard BioTools Inc. (LAB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LAB filings page.
Standard BioTools (LAB) reported third-quarter 2026 revenue of $19.385 million and net income of $13.483 million, versus a $34.687 million net loss a year earlier. The quarter included a $14.977 million continuing-operations loss and $28.460 million income from discontinued operations. Nine-month net income was $113.793 million, including a $172.3 million pretax gain on the SomaScan sale.
Cash and cash equivalents were $267.487 million at September 30, 2026. Net cash used in operating activities was $63.069 million in the first nine months, versus $73.153 million a year earlier. Standard BioTools received $388.2 million in net cash consideration for SomaScan at closing.
The Treeline all-stock merger is expected to close in the fourth quarter of 2026; existing holders are expected to own approximately 16% and former Treeline holders 84% of the combined company on a fully diluted basis, subject to adjustment. Standard BioTools expects to declare one CVR per outstanding share; eligible net proceeds would be paid pro rata in combined-company shares over five years, capped at 76.0 million shares. The $5.5 million cash sale of mass cytometry to Element Biosystems, LLC remains subject to stockholder approval and merger completion; the microfluidics sale closed November 3, 2026.
Standard BioTools Inc. reported slightly lower continuing revenue but a sharp swing to profitability for the six months ended June 30, 2026, largely from divesting its SomaScan Business. Continuing operations generated $41.3 million of revenue, down 2% year over year, with gross margin improving to 53%.
Operating expenses from continuing operations fell 20% to $59.7 million as research and development and selling, general and administrative costs were reduced following prior restructuring, although transaction and integration expenses tied to strategic deals rose to $14.7 million. Continuing operations still posted a net loss of $36.2 million. Including discontinued operations, net income reached $100.3 million, driven by a $172.3 million pre-tax gain on the January 2026 sale of the SomaScan Business to Illumina, which provided $388.2 million of net cash. Cash, cash equivalents and restricted cash rose to $272.1 million, with additional short- and long-term investments of $273.0 million and total liabilities of $87.2 million, leaving the company in a strong net cash position.
Strategically, the company agreed to an all-stock merger with Treeline Biosciences expected to close in the second half of 2026, with Treeline treated as the accounting acquirer and existing Standard BioTools stockholders projected to own about 16% of the combined company. Stockholders are expected to receive contingent value rights tied to monetizing the remaining mass cytometry and microfluidics businesses and certain investments. Subsequent to quarter-end, the company arranged a sale of its mass cytometry business for up to $10.0 million of primarily non-cash consideration and secured a $30.0 million cash settlement from Illumina for terminating earnout and royalty arrangements, which is expected to add a further gain in the third quarter of 2026.
Standard BioTools Inc. reported Q1 2026 results showing modest growth in its core tools business and a large one-time gain from selling its SomaScan proteomics business to Illumina.
Revenue from continuing operations was $21.1 million, up 5% year over year, driven by 35% higher consumables sales, while instrument revenue fell 33%. The company posted a net loss from continuing operations of $14.6 million but overall net income of $127.1 million due to a $172.3 million pre-tax gain on the SomaScan sale, recorded in discontinued operations.
Cash, cash equivalents and investments rose to about $526.5 million, reflecting $363.2 million of cash proceeds from the divestiture plus a $25.0 million contingent receivable and potential future earnouts up to $50.0 million. Operating expenses declined 37% as restructuring and prior-year integration efforts reduced R&D and SG&A, though the company continues to incur restructuring charges. The filing also notes a Nasdaq minimum bid-price deficiency notice, creating a risk of future delisting if compliance is not restored.
Standard BioTools (LAB) reported Q3 2025 results. Revenue from continuing operations was $19.6 million, down from $22.1 million a year ago. Gross profit was $9.5 million. The company posted a net loss of $34.7 million, including a $31.7 million loss from continuing operations and a $3.0 million loss from discontinued operations.
Operating expenses rose, with selling, general and administrative at $26.6 million, research and development at $6.4 million, and restructuring charges of $9.4 million. Cash and cash equivalents were $129.4 million, with $65.5 million in short‑term and $19.5 million in long‑term U.S. Treasury investments.
The SomaScan Business is classified as held for sale and reported as discontinued operations. On June 22, 2025, the company agreed to sell this business to Illumina for up to $425 million, including $350 million in cash at closing and up to $75 million in earnouts. Closing is subject to customary conditions. Shares outstanding were 384,565,414 as of November 2, 2025.
Standard BioTools (LAB) disclosed classification and accounting for the previously announced sale of its SomaScan Business as a discontinued operation. The agreed sale proceeds total $350.0 million plus estimated contingent consideration with an estimated fair value of $396.9 million; the fair value of consideration transferred in the Merger was reported as $444.2 million, and the company recognized a $25.2 million bargain purchase gain. The company allocated $111.9 million of goodwill (100% of total goodwill) to the discontinued operations based on relative fair value, and $30.0 million of deferred revenue related to a Collaboration Agreement was excluded from the disposal group. Management performed recoverability testing on remaining long-lived assets and did not recognize impairment for the periods presented. The filing also discloses continued investments in R&D and commercial infrastructure, a share repurchase authorization up to 50.0 million common shares through March 1, 2026, and maintenance of a valuation allowance against U.S. deferred tax assets.